Assoc Prof Misty Jenkins leads the immunotherapy program within The Brain Cancer Centre. The team’s research is dedicated to discovering new immunotherapy targets in adults and children with brain cancer.
Immunotherapy is an approach that aims to recruit the immune system to fight cancer and has promise in clinical settings.
Our research also focusses on understanding T cell activation and uses cutting edge two-photon microscopy combined with mouse models of brain cancer to investigate the tumour microenvironment and uncover unique biology of brain tumours.
Specifically, we are developing genetically engineered Chimeric Antigen Receptor (CAR) T cells for use as therapy against brain cancer.
Overall our work seeks to advance the field of immunotherapy for brain cancer and improve the outcomes for patients with this devastating disease.
